secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTELO BIOSCIENCES, INC. (ARTL)
CIK:        0001621221
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001640334-25-001334
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artelo raises ~$9.5M private placement to buy Solana; gets UK MHRA nod for Phase 1 trial
--------------------------------------------------------------------------------

- Gross proceeds ~$9.475M from 593,252 shares at $10.20 plus prefunded warrants; also issues Market Priced ($10.20) and $50.00 warrants.
- Net proceeds from shares will be used to purchase SOL; warrant proceeds for working capital and additional SOL.
- UK MHRA provided favorable guidance for first-in-human Phase 1 trial of ART12.11 (CBD:TMP cocrystal) for anxiety/depression.
- Offering expected to close Aug 5, 2025; registration statement to be filed within 15 days of closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621221/000164033425001334/0001640334-25-001334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621221/000164033425001334/artl_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-25-001334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer